An overview of erdosteine antioxidant activity in experimental research

Pharmacological Research

Volumn 55, Issue 4, 2007, Pages 249-254

  Moretti, Maurizio ^a   Marchioni, Carlo Felice ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Antioxidant treatment; Erdosteine; Oxidative stress; Pulmonary disease

Indexed keywords

CATALASE; CISPLATIN; DOXORUBICIN; ERDOSTEINE; FREE RADICAL; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE THIOLACTONE; HYPOCHLOROUS ACID; ISONIAZID; LIPOPOLYSACCHARIDE; NICOTINE; NITRIC OXIDE; PARACETAMOL; SUPEROXIDE DISMUTASE; VANCOMYCIN; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CATALYSIS; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; ISCHEMIA; LIPID PEROXIDATION; LUNG FIBROSIS; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OTOTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TISSUE LEVEL; TOXICITY TESTING;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HUMANS; LIPID PEROXIDATION; LUNG DISEASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RESPIRATORY SYSTEM AGENTS; THIOGLYCOLATES; THIOPHENES;

EID: 34047238871     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.12.006     Document Type: Review

References (57)

1. Dechant K.L., and Noble S. Erdosteine. Drugs 52 (1996) 875-881
2. Braga P.C., Dal Sasso M., and Zuccotti T. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung 50 (2000) 739-746
3. Marchioni C.F., Moretti M., Muratori M., Casadei M.C., Guerzoni P., Scuri R., et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 168 (1990) 285-293
4. Bolser D.C. Evidence-based clinical practice guidelines: cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 129 (2006) 238-249
5. Abuja P.M., and Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta 306 (2001) 1-17
6. Akyol O., Herken H., Uz E., Fadilhoǧlu E., Ural S., Sogut S., et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatr 26 (2002) 995-1005
7. Casazza A.M. Preclinical selection of new anthracyclines. Cancer Treat Rep 70 (1986) 43-49
8. Minotti G., Mancuso C., Frustaci A., Mordente A., Santini S.A., Calafiore A.M., et al. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. J Clin Invest 98 (1996) 650-661
9. Venditti P., Balestrieri M., De Leo T., and Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 38 (1998) 695-702
10. Zhou S., Palmeira C.M., and Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121 (2001) 151-157
11. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4 (1990) 3076-3086
12. Fadillioglu E., Erdogan H., Sogut S., and Kuku I. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. J Appl Toxicol 23 (2003) 71-74
13. Fadilhoǧlu E., and Erdoǧan H. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol Res 47 (2003) 317-322
14. Yagmurca M., Fadillioglu E., Erdogan H., Ucar M., Sogut S., and Irmak M.K. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 48 (2003) 377-382
15. Fadillioglu E., Yilmaz H.R., Erdogan H., and Sogut S. The activities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat hearts subjected to doxorubicin: protective effect of erdosteine. Toxicology 191 (2003) 153-158
16. Anand A.J., and Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27 (1993) 1519-1525
17. Matsushima H., Yonemura K., Ohishi K., and Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 131 (1998) 518-526
18. Baliga R., Zhang Z., Baliga M., Ueda N., and Shah S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53 (1998) 394-401
19. Baliga R., Zhang Z., Baliga M., Ueda N., and Shah S.V. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int 54 (1998) 1562-1569
20. Yildirim Z., Sogut S., Odaci E., Iraz M., Ozyurt H., Kotuk M., et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 47 (2003) 149-156
21. Yilmaz H.R., Iraz M., Sogut S., Ozyurt H., Yildirim Z., Akyol O., et al. The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacol Res 50 (2004) 287-290
22. Ozyurt H., Yildirim Z., Kotuk M., Yilmaz H.R., Yagmurca M., Iraz M., et al. Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner. J Appl Toxicol 24 (2004) 269-275
23. Sogut S., Kotuk M., Yilmaz H.R., Ulu R., Ozyurt H., and Yildirim Z. In vivo evidence suggesting a role for purine-catabolizing enzymes in the pathogenesis of cisplatin-induced nephrotoxicity in rats and effect of erdosteine against this toxicity. Cell Biochem Funct 22 (2004) 157-162
24. Koc A., Duru M., Ciralik H., Akcan R., and Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem 278 (2005) 79-84
25. Kalcioglu M.T., Kizilay A., Gulec M., Karatas E., Iraz M., Akyol O., et al. The protective effect of erdosteine against ototoxicity induced by cisplatin in rats. Eur Arch Otorhinolaryngol 262 (2005) 856-863
26. Nelson S., and Nelson D. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 27 (1995) 147-177
27. Placke M.E., Wyand D.S., and Cohen S.D. Extrahepatic lesions induced by acetaminophen in the mouse. Toxicol Pathol 15 (1987) 381-387
28. Tukel S.S. Effects of acetaminophen on methemoglobin, superoxide dismutase and Na(+)-K+ ATPase activities of human erythrocytes. Biochem Mol Biol Int 35 (1995) 719-724
29. Kapiotis S., Sengoelge G., Hermann M., Held I., Seelos C., and Gmeiner B.M. Paracetamol catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Arterioscler Thromb Vasc Biol 17 (1997) 2855-2860
30. Isik B., Bayrak R., Akcay A., and Sogut S. Erdosteine against acetaminophen induced renal toxicity. Mol Cell Biochem 287 (2006) 185-191
31. Iwamoto T., Kagawa Y., and Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26 (2003) 876-879
32. Oktem F., Arslan M.K., Ozguner F., Candir O., Yilmaz H.R., Ciris M., et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 215 (2005) 227-233
33. Sahin M., Cam H., Olgar S., Tunc S.E., Arslan C., Uz E., et al. Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver. Mol Cell Biochem 291 (2006) 155-160
34. Cicek E., Sutcu R., Gokalp O., Yilmaz H.R., Ozer M.K., Uz E., et al. The effects of isoniazid on hippocampal NMDA receptors: protective role of erdosteine. Mol Cell Biochem 277 (2005) 131-135
35. Hayashi K., Hosoe H., Kaise T., and Ohmori K. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice. J Pharm Pharmacol 52 (2000) 1411-1416
36. Kaise T., Hosoe H., Sano J., and Ohmori K. Effects of KW-9144 on paraquat toxicity in mice and bleomycin-induced pulmonary injury in rats. Jpn J Pharmacol 61 Suppl 1 (1993) 81P
37. Jang Y.Y., Song J.H., Shin Y.K., Han E.S., and Lee C.S. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol 92 (2003) 173-179
38. Demiralay R., Gursan N., Ozbilim G., Erdogan G., and Demirci E. Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury. J Appl Toxicol 26 (2006) 301-308
39. Terzi A., Iraz M., Sahin S., Ilhan A., Idiz N., and Fadillioglu E. Protective effects of erdosteine on rotenone-induced oxidant injury in liver tissue. Toxicol Ind Health 20 (2004) 141-147
40. Bulkley G.B. Free radical-mediated reperfusion injury: a selective review. Br J Cancer Suppl 8 (1987) 66-73
41. Gurel A., Armutcu F., Cihan A., Numanoglu K.V., and Unalacak M. Erdosteine improves oxidative damage in a rat model of renal ischemia-reperfusion injury. Eur Surg Res 36 (2004) 206-209
42. Erdogan H., Fadillioglu E., Yagmurca M., Ucar M., and Irmak M.K. Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury: protective effects of erdosteine and N-acetylcysteine. Urol Res 34 (2006) 41-46
43. Ege E., Ilhan A., Gurel A., Akyol O., and Ozen S. Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord. Eur J Vasc Endovasc Surg 28 (2004) 379-386
44. Koc A., Narci A., Duru M., Gergerlioglu H.S., Akaydin Y., and Sogut S. The protective role of erdosteine on testicular tissue after testicular torsion and detorsion. Mol Cell Biochem 280 (2005) 193-199
45. Weissler J.C. Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis. Am J Med Sci 297 (1989) 91-104
46. Paredi P., Kharitonov S.A., Loukides S., Pantelidis P., du Bois R.M., and Barnes P.J. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115 (1999) 1352-1356
47. Yildirim Z., Turkoz Y., Kotuk M., Armutcu F., Gurel A., Iraz M., et al. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11 (2004) 156-165
48. Yildirim Z., Kotuk M., Iraz M., Kuku I., Ulu R., Armutcu F., et al. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm Pharmacol Ther 18 (2005) 367-373
49. Boyaci H., Maral H., Turan G., Basyigit I., Dillioglugil M.O., Yildiz F., et al. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem 281 (2006) 129-137
50. Demiralay R., Gursan N., and Erdem H. The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells. Toxicology 219 (2006) 197-207
51. Uzun O., Balbay O., Comunoglu N.U., Yavuz O., Nihat Annakkaya A., Guler S., et al. Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine. Acta Histochem 108 (2006) 59-68
52. Basyigit I., Yildiz F., Cekmen M., Duman C., and Bulut O. Effects of erdosteine on smoking-induced lipid peroxidation in healthy smokers. Drugs R D 6 (2005) 83-89
53. MacNee W. Oxidants/antioxidants and COPD. Chest 117 (2000) 303S-317S
54. Agusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 367-370
55. Rahman I., and Kilty I. Antioxidant therapeutic targets in COPD. Curr Drug Targets 7 (2006) 707-720
56. Dal Negro R.W., Visconti M., Micheletto C., and Tognella S. Erdosteine 900 mg/day leads to substantial changes in blood ROS, e-NO and some chemotactic cytokines in human secretions of current smokers. Am J Respir Crit Care Med Suppl 2 (2005) A89
57. Dal Negro R.W., Visconti M., Micheletto C., and Tognella S. Antioxidant effects of erdosteine in current smokers with mild COPD. Eur Respir J 28 Suppl 50 (2006) 429s